Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pancreatic Neoplasms 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Azacitidine 26venetoclax 12Peripheral Blood Stem Cell Transplantation 12fludarabine phosphate 10Mycophenolic Acid 9Whole-Body Irradiation 8Cyclosporine 8Cytarabine 7Cyclophosphamide 6Filgrastim 5Decitabine 5Busulfan 5Methotrexate 4fludarabine 3aldesleukin 3Tacrolimus 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Biopsy 3tipifarnib 2tagraxofusp 2ruxolitinib 2quizartinib 2eprenetapopt 2axatilimab 2X-Rays 2Transplantation 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Chronic × tamibarotene × Clear all
NCT06085638 2024-03-07

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡